

Johnson & Johnson Innovative Medicine
Selected Novel Therapies - Recent Approvals/Potential Filings*
(2023-2030 Key Filings, As Outlined at 2023 Enterprise Business Review)

Selective Highlights as of April 15, 2025

Assets with \$5B+ PYS Potential

Oncology	Immunology
CD20-based CAR-T Lymphoma	icotrokinra Autoimmune Diseases
☑ Intravesical drug releasing system ¹ Bladder Cancer	Neuroscience
✓ RYBREVANT / LAZCLUZE Non Small Cell Lung Cancer	posdinemab Alzheimer's Disease
✓ TALVEY (talquetamab) Relapsed Refractory Multiple myeloma	☑ nipocalimab Autoantibody Diseases
	Select Other Areas
	Milvexian Thrombosis

Assets with \$1 – 5B PYS Potential

Oncology	Immunology
bleximenib Hematologic Malignancies	JNJ-4804 Co-antibody Therapy Inflammatory Bowel Disease
JNJ-5322 (BCMA/GPRC5D/CD3) Hematologic Malignancies	Neuroscience
JNJ-6420 225Ac KLK2 Prostate Cancer	JNJ-1887 sCD59 Geographic Atrophy
JNJ-8343 KLK2 / CD3 Prostate Cancer	RPGR Gene Therapy Retinitis Pigmentosa
JNJ-8543 (CD79/CD20/CD3) Hematologic Malignancies	seltorexant Adjunctive treatment for major depressive disorder with insomnia symptoms
✓ AKEEGA (niraparib/abiraterone) Metastatic castration-resistant prostate cancer (mCRPC)	

- ☑ Submitted in US or EU
✓ Approved in US or EU

1. Previously referred to as TARIS platform. *PYS refers to peak year non-risk adjusted operational sales, including partner sales. Filings/approvals assumed to be in the US and EU unless otherwise noted. This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Niraparib licensed from Tesaro; ExPEC investigational vaccine program developed and commercialized in partnership with Sanofi; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab, Talquetamab); JNJ-1459 was developed through a collaboration with X-CHEM; Lazertinib licensed from Yuhan Corporation; X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx; JNJ-1887 acquired from Hemera Biosciences; Milvexian co-developed with Bristol Myers Squibb; (CAR) T-cell therapies [JNJ-90014496 and JNJ-90009530] AbelZeta collaboration and license agreement; JNJ-2113 licensed from and co-developing with Protagonist Therapeutics, Inc.